3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
114
Carcinoma, Non-Small-Cell Lung
34
Neoplasms
26
Neoplasm Metastasis
19
Prostatic Neoplasms
18
Uveal Melanoma
16
Carcinoma, Renal Cell
16
Lung Neoplasms
14
Pancreatic Neoplasms
13
Diabetes Mellitus, Insulin-Dependent, 12
12
Small Cell Lung Carcinoma
11
Colorectal Neoplasms
10
Carcinoma, Hepatocellular
9
Uterine Cervical Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
8
Breast Neoplasms
8
Sarcoma
7
Carcinoma, Transitional Cell
7
Brain Neoplasms
7
Stomach Neoplasms
6
Mesothelioma
6
Kidney Neoplasms
6
Head and Neck Neoplasms
6
Advanced Cancer
6
Urinary Bladder Neoplasms
5
Recurrence
5
Ovarian Neoplasms
5
Lymphoma, Non-Hodgkin
5
Lymphoma
5
Leukemia, Myeloid, Acute
5
Interventions
Cisplatin
22
Radiotherapy, Intensity-Modulated
12
Fluorouracil
9
Gemcitabine
7
Docetaxel
7
Cetuximab
5
Capecitabine
5
pembrolizumab
4
nimotuzumab
3
nedaplatin
3
Radiotherapy
3
Radiation
3
Carboplatin
3
toripalimab
2
spartalizumab
2
camrelizumab
2
anlotinib
2
Quality of Life
2
Protons
2
Paclitaxel
2
Nivolumab
2
Dexamethasone
2
Chemoradiotherapy
2
tislelizumab
1
raltitrexed
1
penpulimab
1
icotinib
1
fosaprepitant
1
famitinib
1
endostar protein
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Nasopharyngeal Carcinoma
×
Ipilimumab
×
Clear all
NCT03752398
2024-07-05
DUET-3
Xencor, Inc.
Phase 1
Completed
198 enrolled